Beyond CRISPR-Cas9: The Technologies Defining Therapeutic Genome Engineering in 2026

CRISPR Is No Longer the Whole Story

CRISPR-Cas9 transformed biology and launched a new era of therapeutic innovation.

Yet as the first wave of clinical programs matures, researchers are discovering situations where traditional CRISPR approaches may not provide the optimal solution. Precision, editing scope, durability, safety, and delivery continue to drive innovation across the field.

As a result, 2026 is shaping up to be the year when genome engineering truly becomes a multi-technology ecosystem.

The Expanding Genome Engineering Toolkit

Today's developers have a growing arsenal of technologies available, including:

Base editing
Prime editing
Multiplex editing
Epigenome editing
CRISPR activation (CRISPRa)
CRISPR interference (CRISPRi)
Gene writing
CAST systems
Novel nucleases such as Cas12a
Integrase-driven insertion technologies

Each offers unique advantages depending on the disease, target biology, and therapeutic objective.

Rather than replacing CRISPR-Cas9, these approaches are expanding what is scientifically and clinically achievable.

7th Genome Editing Therapeutics Summit 2026 Event Image

Why Now?

Several factors are driving the rapid adoption of next-generation editing technologies:

Developers are targeting increasingly complex diseases that require more than a simple DNA cut-and-repair strategy.
Regulatory momentum is improving. The FDA's proposed Plausible Mechanism Pathway could accelerate development of innovative editing therapies for ultra-rare diseases and create opportunities for emerging platforms to reach patients faster.
Investors continue to back companies capable of demonstrating meaningful technological differentiation. The industry's largest partnerships increasingly focus on platform innovation, delivery capability, and expanded editing functionality.

The Innovators Defining 2026

Many of the most exciting companies in genome engineering are expected to contribute to discussions at the 7th Genome Editing Therapeutics Summit.

Prime Medicine continues advancing the possibilities of prime editing.

Metagenomi Therapeutics is helping expand the in vivo editing toolkit through novel systems and delivery strategies.

Arbor Biotechnologies and Scribe Therapeutics are each pursuing differentiated approaches to therapeutic genome engineering.

Alongside these innovators, established leaders including Beam Therapeutics, Intellia Therapeutics, and major pharmaceutical partners are helping demonstrate how these technologies can reach clinical maturity.

The Real Challenge Is Application

The greatest innovation challenge facing the field is no longer technology creation. It's technology application.

Can these tools be delivered efficiently? Can safety concerns be mitigated? Can regulators be satisfied? Can they scale commercially? And most importantly, can they deliver meaningful outcomes for patients?

These questions are driving a broader shift across the industry toward translational discussions, clinical strategy, regulatory readiness, and product development.

The Industry's Defining Conversation

The 7th Genome Editing Therapeutics Summit is uniquely positioned to address these challenges by focusing on the applications of breakthrough technologies rather than the technologies alone.

Attendees will explore how emerging tools are being applied across rare diseases, common diseases, oncology, and next-generation therapeutic development, while addressing the practical realities of moving from benchtop innovation to clinical success.

CRISPR may have opened the door to therapeutic genome engineering, but the next generation of technologies is determining how far the field can go.

In 2026, the future belongs not to a single platform, but to the innovators capable of turning technological breakthroughs into patient impact.